Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zila starts phase III US trial for oral cancer test:

This article was originally published in Clinica

Executive Summary

Zila has begun a US phase III clinical trial of its oral cancer detection product, OraTest. The trial is expected to enrol less than 4,000 high-risk patients and is anticipated to be completed in a year, once all investigator sites are active. An interim analysis will be undertaken to determine the total number of patients required in the study. In a SEC filing this month, the Phoenix, Arizona firm said that upon the trial's completion, and assuming that the clinical endpoints have been met, it would take it around 3-6 months to prepare an OraTest marketing application for submission to the FDA. According to the American Dental Association, over 30,000 people are diagnosed with oral cancer annually in the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058196

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel